Health
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia – The Lancet
The heterologous rAd26 and rAd5 vector-based COVID-19 vaccine has a good safety profile
and induced strong humoral and cellular immune responses in participants. Further
investigation is needed of the effectiveness of this vaccine for prevention of COVID-19.
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.
Copyright © 2020 Elsevier Inc. except certain content provided by third parties.
Privacy Policy Terms and Conditions…
-
Noosa News17 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
Noosa News15 hours agoNo matter what happens in his Origin debut, history beckons for rookie maroon Robert Toia
-
Noosa News17 hours agoGood character references restricted in rape cases in Queensland
-
Noosa News21 hours agoBrisbane Broncos star Reece Walsh says punching friend in face ‘not a good look’